Company: QTIWW
Filing Date: 2025-11-03
Form Type: S-1
Source: 0001628280-25-048373
Chunk: 365

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-11-03
Form: S-1
Chunk 365
---
2023 |
|:------------------------------------|:----|:------------------------|--------:|:----|:--|--------:|
| Research and development            |     | $                       |  58,270 |     | $ | 105,255 |
| Selling, general and administrative |     |                         | 231,525 |     |   | 604,139 |
|                                     |     | $                       | 289,795 |     | $ | 709,394 |

Nostock-based compensation expense was capitalized to inventory for years ended December 31, 2024 and 2023.

As of December 31, 2024, the total unrecognized compensation cost related to all nonvested stock options was $ 758,294and the weighted-average period over which it is expected to be recognized is 2.1years.

#### 13. National Institutes of Health Subaward
On August 18, 2022, the Company was awarded a grant of up to $ 1,078,347as a subaward through the Board of Trustees of the University of Illinois for the purpose of developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy. The grant is a cost reimbursement subaward that is allocated annually over five years, subject to the availability of funds and satisfactory progress of the project. The award expires July 31, 2027 and may be terminated by either party with 30days written notice. Any grant proceeds received do not require repayment. As of December 31, 2024, the Company incurred total costs of $ 388,359against the year one allocation of $ 351,994, against the year two allocation of $ 194,566, and against the year three allocation of $ 119,000. During the year ended December 31, 2024, the Company incurred costs of $ 39,305, of which $ 23,509of grant income was recognized as an offset to research and development expense and $ 15,796was recognized as an offset to selling, general and administrative expense in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2023, the Company incurred costs of $ 318,276, of which $ 277,037of grant income was recognized as an offset to research and development expense and $ 41,239was recognized as an offset to selling, general and administrative expense in the consolidated statements of operations and comprehensive loss. As of December 31,